Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma
- PMID: 16103980
- DOI: 10.1055/s-2005-915649
Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma
Abstract
Hepatocellular carcinoma (HCC) is associated with hepatitis B virus (HBV) infection in approximately 50% of cases, although the oncogenic mechanisms of HBV are not well understood. Vaccination for HBV has successfully lowered the rates of both HBV infection and HCC. Once chronic HBV infection is established, the objective of antiviral treatment is to prevent disease progression to liver cirrhosis or HCC, or both. Studies have found HBV DNA level to be a strong predictor for the development of cirrhosis and HCC, irrespective of the status of viral and biochemical factors. This article reviews recent clinical trials evaluating sustained viral suppression with interferon alfa and lamivudine. The results support the need to reduce viral load as an important therapeutic goal. For HCC not prevented by these measures, surveillance using ultrasonography and serum alpha-fetoprotein assay every 3 to 6 months is able to detect HCC at an earlier stage and allows curative therapy with survival benefit.
Similar articles
-
Prevention of hepatocellular carcinoma in hepatitis B virus infection.J Gastroenterol Hepatol. 2009 Aug;24(8):1352-7. doi: 10.1111/j.1440-1746.2009.05985.x. J Gastroenterol Hepatol. 2009. PMID: 19702903 Review.
-
Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.Oncology. 2011;81 Suppl 1:41-9. doi: 10.1159/000333258. Epub 2011 Dec 22. Oncology. 2011. PMID: 22212935 Review.
-
Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.J Gastroenterol Hepatol. 2010 Apr;25(4):657-63. doi: 10.1111/j.1440-1746.2009.06167.x. J Gastroenterol Hepatol. 2010. PMID: 20492323
-
Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy.Antivir Ther. 2006;11(6):669-79. Antivir Ther. 2006. PMID: 17310811 Review.
-
[Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].Z Gastroenterol. 2008 Jan;46(1):69-80. doi: 10.1055/s-2007-963684. Z Gastroenterol. 2008. PMID: 18188819 Review. German.
Cited by
-
Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LC-MS/MS.J Cancer Res Clin Oncol. 2010 Aug;136(8):1151-9. doi: 10.1007/s00432-010-0762-6. Epub 2010 Feb 4. J Cancer Res Clin Oncol. 2010. PMID: 20130913
-
SASLT practice guidelines for the management of hepatitis B virus.Saudi J Gastroenterol. 2014 Jan-Feb;20(1):5-25. doi: 10.4103/1319-3767.126311. Saudi J Gastroenterol. 2014. PMID: 24496154 Free PMC article. No abstract available.
-
Prevention by Lamivudine of hepatocellular carcinoma in patients infected with hepatitis B virus.Gut Liver. 2007 Dec;1(2):151-8. doi: 10.5009/gnl.2007.1.2.151. Epub 2007 Dec 31. Gut Liver. 2007. PMID: 20485632 Free PMC article.
-
[4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009].Wien Klin Wochenschr. 2010 May;122(9-10):280-302. doi: 10.1007/s00508-009-1298-0. Epub 2010 May 4. Wien Klin Wochenschr. 2010. PMID: 20443069 German.
-
Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.World J Gastroenterol. 2014 Sep 7;20(33):11595-617. doi: 10.3748/wjg.v20.i33.11595. World J Gastroenterol. 2014. PMID: 25206267 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical